Urovant Sciences Ltd.
Urovant Sciences Ltd. (UROV): 1 pipeline candidate · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.0 months
D/E -1.75 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Urovant Sciences Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$73.7M
Quarterly Burn
$46.8M
Runway
5.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| uro-902 | Phase 2 |
Frequently asked questions
How many drug candidates are in Urovant Sciences Ltd.'s pipeline?
Urovant Sciences Ltd. (UROV) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Urovant Sciences Ltd.'s lead drug candidate?
Urovant Sciences Ltd.'s most advanced tracked candidate is uro-902 (Phase 2) for overactive bladder (OAB) in patients who have failed oral pharmacological therapy.
What is Urovant Sciences Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Urovant Sciences Ltd. has approximately 5.0 months of cash runway.
Who is the CEO of Urovant Sciences Ltd.?
Sumitovant Biopharma Inc is the chief executive officer of Urovant Sciences Ltd. (UROV).
Get the full picture on Urovant Sciences Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.